Form 4: Coya Therapeutics Chief Medical Officer Acquires Shares

Coya Therapeutics' Chief Medical Officer, Fred Grossman, acquired 2,710 shares of common stock at a price of $7.37 per share on November 11, 2024.

Summary

• Fred Grossman, the Chief Medical Officer of Coya Therapeutics, Inc., purchased 2,710 shares of the company's common stock.
• The transaction occurred on November 11, 2024.
• The price per share was $7.37.
• The shares were acquired directly by Mr. Grossman.

Sentiment

Score: 6

Explanation: The document is a neutral disclosure of a stock purchase by an executive. It doesn't inherently indicate positive or negative sentiment, but insider buying is often viewed as a positive sign.

Positives

• The purchase of shares by a key executive may indicate confidence in the company's future prospects.

Industry Context

This is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is relatively small in volume, suggesting it is not a major market-moving event.

Stakeholder Impact

• The stock purchase may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Coya Therapeutics, Fred Grossman, Chief Medical Officer, stock acquisition, insider trading, share purchase